Nadeem, O., Aranha, M., Redd, R., Koontz, M., Matous, J., Yee, A., Zonder, J., Kin, A., Magidson, S., Lightbody, E., Wu, T., Chabrun, F., Alberge, J., Dutta, A., Perry, J., Sturtevant, A., Rahmat, M., Tsuji, J., Davie, C., Ricciardi, C., Arters, F., Marto, M., Goguen, A., Rosenblatt, J., O'Donnell, E., Laubach, J., Richardson, P., Getz, G., Trippa, L., Sklavenitis-Pistofidis, R., Ghobrial, I. (2025). Results of the Phase II d-PRISM study: Daratumumab in high-risk MGUS and low-risk smoldering myeloma. Blood. https://doi.org/10.1182/blood-2025-1533